Asthma patient baseline characteristics by treatment group
| Placebo | Salmeterol | Fluticasone | |
| Subjects n | 16 | 13 | 16 |
| Males/females n | 7/9 | 8/5 | 11/5 |
| Age yrs | 33 (22–68) | 38 (20–70) | 42 (22–63) |
| ICS dose µg·day−1 | 400 (200–500) | 400 (200–500) | 400 (200–500) |
| Atopic/nonatopic n | 12/4 | 13/0 | 11/5 |
| PD20 mg | 0.011 (0.001–0.16) | 0.022 (0.01–0.56) | 0.021 (0.003–0.46) |
| FEV1 % pred | 83 (61–109) | 84 (63–106) | 80 (61–102) |
| 24-h symptom score | 1.07 (0.57–4.21) | 1.21 (0.01–3.29) | 1.39 (0.57–2.57) |
| 24-h salbutamol use puffs·day−1 | 1.07 (0.57–5.50) | 1.21 (0.57–4.86) | 1.82 (0.50–5.36) |
Data are presented as median (range), and as geometric mean (range) for provocative dose of methacholine causing a 20% fall in forced expiratory volume in one second (FEV1) (PD20)
Full clinical details are presented in 14
ICS: inhaled corticosteroid
% pred: percentage of the predicted value